An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
U.S. stocks are drifting near their records after the latest inflation update boosted hopes that more help for the economy ...
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Every step of the way, Rose Booker, formally of the Durham Catholic District School Board, has worked tirelessly to make sure ...
A new study by Monash University medicine safety experts found the use of gabapentinoids – medicines widely used to treat neuropathic pain – increased the risk of hip fractures, especially in older ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
The S&P 500 slipped 0.3% on Tuesday, Nov. 12, the benchmark index's first negative trading day since last week's election.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback